Stanford researcher criticizes FDA plans to reduce oversight of off-label drug use

Proposed guidelines from the U.S. Food and Drug Administration would allow companies to market more drugs for unapproved uses and are a step in the wrong direction, said a researcher from the Stanford University School of Medicine.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news126416913.html">Stanford researcher criticizes FDA plans to reduce oversight of off-label drug use</a></p> <p>Proposed guidelines from the U.S. Food and Drug Administration would allow companies to market more drugs for unapproved uses and are a step in the wrong direction, said a researcher from the Stanford University School of Medicine.</p>